Abstract
Multisite artery disease (MSAD) affects 15% to 30% of patients with clinically manifest atherosclerosis, and has a relevant negative impact on prognosis. However, studies specifically focused on MSAD are very few, and available evidence is scarce. Importantly, patients with MSAD require an integrated management, possibly by a "Vascular Team" composed of the different specialists involved in the treatment of atherosclerosis. A multi-disciplinary, patient-centered approach is mandatory to deal with the variety of clinical scenarios and comorbidities found in MSAD patients. The risk/benefit ratio for multi-site arterial revascularization should always be carefully assessed in MSAD patients, taking into account the additional risks of interventions in this subset of patients. Many therapeutic options have been proposed for multisite revascularization, but little evidence is currently available to support specific recommendations. Percutaneous revascularization of the different arterial districts, when feasible, appears promising because of the lower operative morbidity and mortality.
Keywords: Multisite artery disease, atherosclerosis, carotid artery stenosis, coronary artery disease, lower extremity artery disease, revascularization, carotid artery stenting, carotid endarterectomy, coronary artery bypass grafting, percutaneous coronary intervention, peripheral angioplasty, peripheral artery bypass, multi-disciplinary, guidelines, vascular team
Current Vascular Pharmacology
Title:Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures
Volume: 10 Issue: 6
Author(s): Marco De Carlo and Leonardo Misuraca
Affiliation:
Keywords: Multisite artery disease, atherosclerosis, carotid artery stenosis, coronary artery disease, lower extremity artery disease, revascularization, carotid artery stenting, carotid endarterectomy, coronary artery bypass grafting, percutaneous coronary intervention, peripheral angioplasty, peripheral artery bypass, multi-disciplinary, guidelines, vascular team
Abstract: Multisite artery disease (MSAD) affects 15% to 30% of patients with clinically manifest atherosclerosis, and has a relevant negative impact on prognosis. However, studies specifically focused on MSAD are very few, and available evidence is scarce. Importantly, patients with MSAD require an integrated management, possibly by a "Vascular Team" composed of the different specialists involved in the treatment of atherosclerosis. A multi-disciplinary, patient-centered approach is mandatory to deal with the variety of clinical scenarios and comorbidities found in MSAD patients. The risk/benefit ratio for multi-site arterial revascularization should always be carefully assessed in MSAD patients, taking into account the additional risks of interventions in this subset of patients. Many therapeutic options have been proposed for multisite revascularization, but little evidence is currently available to support specific recommendations. Percutaneous revascularization of the different arterial districts, when feasible, appears promising because of the lower operative morbidity and mortality.
Export Options
About this article
Cite this article as:
De Carlo Marco and Misuraca Leonardo, Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520855
DOI https://dx.doi.org/10.2174/157016112803520855 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design Global Life-Long Health Benefits of Repression of Hypothalamic NPY System by Central Leptin Gene Therapy
Current Topics in Medicinal Chemistry Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Editorial [Hot Topic: Neural Control of the Vasculature: Pharmacological Targets in Vascular Disease (Guest Editors: Andrzej Loesch and Michael R. Dashwood)]
Current Vascular Pharmacology Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Vascular and Cellular Calcium in Normal and Hypertensive Pregnancy
Current Clinical Pharmacology Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature
Current Diabetes Reviews Hemodynamic Behavior of Coronary Stents in Straight and Curved Arteries
Current Nanoscience